EUVIMEDEUVIMED entdecken
Crossref

Effect of P-glycoprotein and Cotreatment with Sofosbuvir on the Intestinal Permeation of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide Fumarate

Martin Huliciak, Ivona Lhotska, Hana Kocova-Vlckova, Veronika Halodova, Tomas Dusek, Filip Cecka, Frantisek Staud, Ivan Vokral, Lukas Cerveny

Pharmaceutical Research · 2023

DOI: 10.1007/s11095-023-03581-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Research, 2023. Verfasst von Martin Huliciak und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Akademika Heyrovskeho 1203, 50005, Hradec Kralo…. Hauptthemen laut MEDLINE: Anti-HIV Agents, HIV Infections. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 69 Literaturangaben. Gefördert von: Grantová Agentura, Univerzita Karlova, Grantová Agentura České Republiky, Ministerstvo Školství, Mládeže a Tělovýchovy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: We aimed to compare the effects of P-glycoprotein (ABCB1) on the intestinal uptake of tenofovir disoproxil fumarate (TDF), tenofovir alafenamide fumarate (TAF), and metabolites, tenofovir isoproxil monoester (TEM) and tenofovir (TFV), and to study the molecular mechanism of drug-drug interaction (DDI) between sofosbuvir (SOF) and TDF/TAF. METHODS: Bidirectional transport experiments in Caco-2 cells and accumulation studies in precision-cut intestinal slices prepared from the ileal segment of rodent (rPCIS) and human (hPCIS) intestines were performed. RESULTS: TDF and TAF were extensively metabolised but TAF exhibited greater stability. ABCB1 significantly reduced the intestinal transepithelial transfer and uptake of the TFV(TDF) and TFV(TAF)-equivalents. However, TDF and TAF were absorbed more efficiently than TFV and TEM. SOF did not inhibit intestinal efflux of TDF and TAF or affect intestinal accumulation of TFV(TDF) and TFV(TAF)-equivalents but did significantly increase the proportion of absorbed TDF. CONCLUSIONS: TDF and TAF likely produce comparable concentrations of TFV-equivalents in the portal vein and the extent of permeation is reduced by the activity of ABCB1. DDI on ABCB1 can thus potentially affect TDF and TAF absorption. SOF does not inhibit ABCB1-mediated transport of TDF and TAF but does stabilise TDF, albeit without affecting the quantity of TFV(TDF)-equivalents crossing the intestinal barrier. Our data thus suggest that reported increases in the TFV plasma concentrations in patients treated with SOF and TDF result either from a DDI between SOF and TDF that does not involve ABCB1 or from a DDI involving another drug used in combination therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-HIV AgentsHIV InfectionsHumansTenofovirSofosbuvirATP Binding Cassette Transporter, Subfamily B, Member 1Caco-2 CellsAdenineATP Binding Cassette Transporter, Subfamily BFumaratesAlanine

Stichwörter der Autor:innen

P-glycoproteinintestinal permeabilitysofosbuvirtenofovir alafenamide fumaratetenofovir disoproxil fumarate

Substanzen

TenofovirSofosbuvirAnti-HIV AgentsATP Binding Cassette Transporter, Subfamily B, Member 1AdenineATP Binding Cassette Transporter, Subfamily BFumaratesAlanine

Autor:innen und Institutionen

  • Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Akademika Heyrovskeho 1203, 50005, Hradec Kralove, Czech Republic.
  • Department of Analytical Chemistry, Faculty of Pharmacy in Hradec Kralove, Charles University, Akademika Heyrovskeho 1203, 500 05, Hradec Kralove, Czech Republic.
  • Department of Surgery, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic.
  • Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Akademika Heyrovskeho 1203, 50005, Hradec Kralove, Czech Republic. cervenyl@faf.cuni.cz.

Förderung

  • Grantová Agentura, Univerzita Karlova
  • Grantová Agentura České Republiky
  • Ministerstvo Školství, Mládeže a Tělovýchovy

Zitieren

APA

Huliciak, M., Lhotska, I., Kocova-Vlckova, H., Halodova, V., Dusek, T., Cecka, F., Staud, F., Vokral, I., & Cerveny, L. (2023). Effect of P-glycoprotein and Cotreatment with Sofosbuvir on the Intestinal Permeation of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide Fumarate. Pharmaceutical Research. https://doi.org/10.1007/s11095-023-03581-2

Vancouver

Huliciak M, Lhotska I, Kocova-Vlckova H, Halodova V, Dusek T, Cecka F, et al. Effect of P-glycoprotein and Cotreatment with Sofosbuvir on the Intestinal Permeation of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide Fumarate. Pharmaceutical Research. 2023. doi:10.1007/s11095-023-03581-2

BibTeX
@article{Huliciak2023,
  author = {Huliciak, Martin and Lhotska, Ivona and Kocova-Vlckova, Hana and Halodova, Veronika and Dusek, Tomas and Cecka, Filip and Staud, Frantisek and Vokral, Ivan and Cerveny, Lukas},
  title = {Effect of P-glycoprotein and Cotreatment with Sofosbuvir on the Intestinal Permeation of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide Fumarate},
  journal = {Pharmaceutical Research},
  year = {2023},
  doi = {10.1007/s11095-023-03581-2}
}
Kostenlos starten →